About niraparib
PARP inhibitor anticancer medicine
Used for
- Maintenance treatment for certain ovarian, fallopian tube, or primary peritoneal cancers after response to platinum chemotherapy.
- Treatment of certain advanced prostate cancers with abiraterone and prednisone.
Usual adult dose
Usually 200 or 300 mg by mouth once daily for ovarian cancer, based on weight and platelet count. Prostate cancer dosing follows the combination product regimen.
Common side effects
- Low platelet, red blood cell, or white blood cell counts
- Nausea, constipation, vomiting, or diarrhea
- Fatigue, headache, or dizziness
- High blood pressure
Important warnings
- Can cause serious bone marrow problems, including rare blood cancers; blood tests are required.
- Blood pressure and heart rate can rise; monitoring is needed.
- May cause fetal harm; effective contraception is required during treatment and for six months afterward.
- Doses vary by cancer type and patient factors; treatment requires specialist supervision.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for six months after the last dose.
Breastfeeding
Do not breastfeed during treatment or for one month after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors may increase niraparib exposure.
- Review all medicines and supplements with the oncology team before use.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.